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brachytherapy. However, magnetic resonance imaging (MRI) provides greater anatomic detail than
TRUS. We compared treatment plans generated using TRUS, endorectal coil MRI (erMRI), and
standard body array coil MRI (sMRI).
METHODS ANDMATERIALS: Treatment plans were used from patients treated with permanent,
stranded-seed 125I brachytherapy in a prospective trial. All men underwent pretreatment planning
based on TRUS, and all underwent erMRI before treatment and sMRI 30 days after the implant. Treat-
ments for 20 consecutive patients were replanned on sMRI and erMRI images by investigators blinded
to TRUS-based plans. Prostate volume/dimensions, radioactivity-to-prostate-volume ratio, and dosi-
metric parameters were compared.
RESULTS: Compared with TRUS, mean prostate volume measured by erMRI was smaller, medial-
lateral diameter was larger, and anterior-posterior diameter was smaller, suggesting that the endorectal
coil produced anatomic distortions. Craniocaudal prostate length was smaller on both types of MRI
than on TRUS, suggesting that TRUS overestimates prostate length. Activity per volume was 7.5%
lower for plans based on sMRI than on TRUS (0.901 vs. 0.974 mCi/cm3, p!0.001). sMRI plans
had similar coverage of the planning target volume (PTV) (dose to 90% of the prostate [D90]
116.6% sMRI vs. 117.5% TRUS, p5 0.526) and improved dose homogeneity (percentage of PTV
receiving 150%of theprescriptiondose [V150] 47.4%sMRIvs. 53.8%TRUS,p5 0.001 andpercentage
of PTV receiving 200% of the prescription dose [V200] 16.6% sMRI vs. 19.2% TRUS, p!0.001).
CONCLUSIONS: Staging erMRI should not be routinely used for treatment planning because it
produces anatomic distortion. sMRI may have treatment planning advantages over TRUS because
of superior soft-tissue delineation of the prostate and adjacent normal tissue structures.  2013
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Transrectal ultrasound (TRUS) is a well-established (1)
and commonly used (2) imaging modality for planning
prostate brachytherapy. TRUS is the standard imaging
modality when used for either preplanning or intraopera-
tive planning (3, 4). However, TRUS has important limi-
tations such as interoperator variability in determining
prostate volume and dimensions (5); this seems to be
due in part to operator experience (6e8) and in part to
limitations in TRUS image resolution. Any uncertainty
in prostate delineation is significant for planning brachy-
therapy given the high conformality and rapid dose falloff
inherent in brachytherapy. Uncertainties in prostatehed by Elsevier Inc. All rights reserved.
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than are necessary to cover the volume, or seeds being
placed outside the prostate in adjacent structures such as
the bladder neck, anterior rectal wall, urogenital dia-
phragm, and penile bulb.
Use of improved imaging modalities would help to
enhance the quality of brachytherapy for prostate cancer.
Computed tomography (CT) is imprecise for visualizing
the prostate (9) and is associated with significant uncertainty
and variability in delineating prostate dimensions (10e12);
prostate volumes estimated from CT scans have been shown
to be up to 50% larger than those estimated using TRUS (13,
14). Magnetic resonance imaging (MRI) has been explored
as an imaging modality for prostate biopsy (15, 16) and for
prostate brachytherapy (17, 18). MRI-based estimates of
prostate volume have been shown to correlate well with
TRUS-based volumes (19, 20), with significantly improved
resolution and visualization of prostate anatomy. Moreover,
endorectal coil MRI (erMRI) has demonstrated even greater
resolution than standard body array coil MRI (sMRI) for
prostate visualization (21, 22), which could provide further
advantages for treatment planning.
The purpose of the present study was to compare
TRUS, the standard modality used for planning prostate
brachytherapy at MD Anderson Cancer Center, with erM-
RI and sMRI for brachytherapy planning. We aimed to
explore the feasibility of using erMRI and sMRI for treat-
ment planning, and also to determine the advantages and
disadvantages of each modality. Specifically, we aimed to
compare prostate volume and dimensions, total activity-
to-prostate-volume ratio, and dosimetric parameters ob-
tained from TRUS, erMRI, and sMRI-based plans to
quantify anatomic and treatment planning differences
between the three imaging modalities.Methods and materials
Patient selection
Cases were selected for analysis from men enrolled in
a prospective phase II trial at MD Anderson who received
a permanent prostate 125I stranded-seed implant as mono-
therapy for histologically confirmed adenocarcinoma of the
prostate. Patients had clinical stage T1ceT2bN0M0 disease
(American Joint Committee on Cancer [AJCC] Cancer
Staging Manual 6th edition, 2002) and intermediate-risk
disease, defined as (1) Gleason score!7, prostate-specific
antigen [PSA] level 10e15 ng/mL; or (2) Gleason score 7,
PSA!10. Prostate volume had to be #60 cm3 as measured
by TRUS, and each patient had to have an American Urolog-
ical Association Symptom Score of #15. Other exclusion
criteria were prior transurethral resection of the prostate,
cryosurgery, pelvic radiation, chemotherapy, or androgen
deprivation therapy. Twenty consecutive patients from this
protocol were chosen for the present retrospective anatomic
and dosimetric analysis.Staging, imaging, and treatment
All patients underwent a history and physical examina-
tion (including a digital rectal examination), serum PSA
measurements, pelvic CT scan, and TRUS before treatment
to rule out pubic arch interference and ensure the technical
feasibility of a sufficiently high-quality implant. All TRUS
studies were performed by a radiation oncologist (SJF)
using the Siemens SONOLINE G20 ultrasound system with
an Endo P-II Intracavitary Transducer. As part of the
protocol, all patients underwent erMRI scanning before
treatment to rule out extraprostatic extension or seminal
vesicle involvement. The VariSeed 8.0 planning system
(Varian Medical Systems, Palo Alto, CA) was used for
treatment planning. The preimplant TRUS images were
used to generate a preplan, and a standard modified periph-
eral loading technique with stranded seeds was used for all
patients. The planning target volume (PTV) was defined as
a 3-mm expansion from the prostate anteriorly and later-
ally, a 5-mm expansion cranially and caudally, and no
expansion posteriorly. All treatment plans used a prescrip-
tion dose of 145 Gy with 125I sources and aimed to satisfy
the following dosimetric parameters: percentage of PTV
receiving 100% of the prescription dose (PTV V100)
O95%, percentage of PTV receiving 150% of the prescrip-
tion dose (PTV V150)!60%, percentage of PTV receiving
200% of the prescription dose (PTV V200) !20%, rectal
volume receiving 100% of the prescription dose (R100)!
1 cm3, and urethral volume receiving 200% of the prescrip-
tion dose (U200) to be near 0. All patients underwent perma-
nent interstitial prostate implants, and intraoperative TRUS
was used to guide needle placement and verify the posi-
tioning of the strands. In addition to CT scans on Day
0 and Day 30 after the implant, all patients underwent
sMRI on postimplant Day 30.MRI-based planning
For the purposes of the present study, the preimplant
erMRI and 30-day postimplant sMRI images were used
to retrospectively replan the seed placement for each
patient. The T2-weighted series for both the erMRI and
sMRI were imported into the VariSeed system. Contours
for the prostate, bladder, rectum, urethra, and seminal
vesicles were outlined independently on the erMRI and
sMRI. All contours were approved by the two reviewers.
The PTV was defined in the same way as for the actual
treatment, as a 3-mm expansion from the prostate anteri-
orly and laterally, a 5-mm expansion cranially and
caudally, and no expansion posteriorly. The erMRI- and
sMRI-based plans were jointly developed by a medical
dosimetrist and radiation oncologist who were blinded
to the TRUS-based plans; they used the same standard
modified peripheral loading technique as that used for
TRUS-based plans, optimized to the anatomic detail
visible on the MRI. Planning was done independently
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were designed to satisfy the same dosimetric parameters
as those used in the actual treatments: PTV V100O95%,
V150!60%, V200!20%, R100!1 cm
3, and U200 near 0.
Statistical analysis
Prostate volume and dimensions, the radioactivity-to-
prostate-volume ratio, and dosimetric parameters (PTV
V100, V150, V200; dose to 90% of the prostate [D90]; R100;
U200) were compared for the three modalities (TRUS, erM-
RI, and sMRI) by using the Wilcoxon signed-rank test for
paired samples. Comparisons were performed pair wise
between each of the MRI modalities and TRUS. All
p-values were obtained by using two-tailed tests, and
a p-value of!0.05 was considered statistically significant.
Data were analyzed with PASW Statistics 17.0 (SPSS, Inc.,
Chicago, IL).Results
Distortion of prostate anatomy with endorectal coil
To determine whether the different imaging modalities
resulted in differences in the visualized anatomy of the
prostate, the mean prostate volume and dimensions
measured by TRUS, erMRI, and sMRI were compared
(Table 1). When compared with TRUS, the mean prostate
volume measured by erMRI was smaller (29.5 vs.
32.5 cm3 by TRUS, p5 0.001), the mean medial-lateral
diameter was larger (5.01 erMRI vs. 4.65 cm by TRUS,
p!0.001), and the mean anterior-posterior diameter was
smaller (2.69 vs. 3.06 cm by TRUS, p!0.001), suggesting
that the use of the endorectal coil caused substantial
anatomic distortion (Fig. 1).
In contrast, no significant difference was found between
the mean prostate volume estimated by sMRI and that esti-
mated by TRUS (33.9 cm3 sMRI vs. 32.5 cm3 TRUS,
p5 0.076). Moreover, the difference in medial-lateral diam-
eter between these twomodalities was less than 2 mm, and of
only borderline significance ( p5 0.050), although the
anterior-posterior diameter was larger on sMRI (3.50 cm
sMRI vs. 3.06 cm TRUS, p!0.001). These smallerTable 1
Prostate volume and dimensions for each imaging modality
Parameter
TRUS sMRI
Measure (95% CI) Measure (
Volume (cm3) 32.5 (29.7e35.2) 33.9 (31.1
Medial-lateral diameter (cm) 4.65 (4.50e4.79) 4.48 (4.38
Anterior-posterior diameter (cm) 3.06 (2.92e3.20) 3.50 (3.34
Superior-inferior length (cm) 4.23 (4.02e4.43) 3.55 (3.40
TRUS5 transrectal ultrasound; sMRI5 standard body array coil magnetic r
CI5 confidence interval; MRI5magnetic resonance imaging.
*p-Values are for each MRI modality compared with TRUS.differences are likely attributable to the anatomic distortion
caused by the TRUS probe. Notably, sMRI- and erMRI-
based measurements of prostate volume, anterior-posterior
diameter, and medial-lateral diameter were all different from
one another ( p!0.001 for all comparisons).
Overestimation of prostate length with TRUS
Because accurate measurement of craniocaudal prostate
length is a critically important step in brachytherapy treat-
ment planning and delivery, we compared this measure-
ment among the three imaging modalities and found that
craniocaudal length was shorter when estimated by either
type of MRI than by TRUS (TRUS 4.23 cm, erMRI
3.71 cm, p!0.001; sMRI 3.55 cm, p!0.001) (Table 1).
This suggests that TRUS may overestimate prostate length,
which could result in seeds inadvertently being placed in
the urogenital diaphragm or penile bulbda hypothesis that
was confirmed by review of postimplant MRIs (Fig. 2). A
small difference in craniocaudal length of less than 2 mm
was noted between erMRI and sMRI ( p5 0.040).
Treatment planning difficulties with erMRI
The anatomic distortions induced by the endorectal coil
made treatment planning with the erMRI images problem-
atic. Specifically, the flattening of the gland against the
pubic bone (Fig. 1) resulted in nonstandard, often asym-
metric loading patterns to adequately cover the PTV. In
addition, the compression of the prostate placed it in close
proximity to the rectum over much of its length, which
would have resulted in some needles penetrating the ante-
rior rectal wall to achieve adequate peripheral zone
coverage. A representative midgland slice for 1 patient is
shown in Fig. 3, demonstrating needle and seed placement
for all the three imaging modalities.
One metric that was used to quantify the differences in
needle loading required for the erMRI-based plans was the
number of seeds per strand. To produce adequate PTV
coverage over the distorted prostate gland, erMRI-based
plans would have fewer seeds per strand than TRUS-based
plans (3.33 vs. 3.54, p5 0.021). Of note, no significant
difference was found between the number of seeds per strand
on sMRI compared with TRUS (3.45 vs. 3.54, p5 0.322).erMRI
95% CI) p-Value* Measure (95% CI) p-Value*
e36.7) 0.076 29.5 (27.0e32.0) 0.001
e4.59) 0.05 5.01 (4.85e5.17) !0.001
e3.67) !0.001 2.69 (2.57e2.81) !0.001
e3.70) !0.001 3.71 (3.53e3.89) !0.001
esonance imaging; erMRI5 endorectal coil magnetic resonance imaging;
Fig. 1. Anatomic distortion with endorectal coil magnetic resonance imaging. T2-weighted (a) axial and (b) sagittal images from a patient demonstrate the
significant anatomic distortion caused by introduction of an endorectal coil (red dotted line on the sagittal image highlights the prostate shape). (For inter-
pretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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To determine whether the differences in prostate delinea-
tion between the different imaging modalities affected the
amount of radioactivity required to cover the target volume,
we compared the amounts of radioactivity between TRUS-
based plans with plans based on each MRI modality.
Comparing the ratio of activity per volume instead of total
activity eliminates any confounding effect of prostate volume
differences between the imaging modalities. The mean
activity-per-volume ratio of the sMRI-based plans was lower
than that for TRUS-based plans (0.901 vs. 0.974 mCi/cm3,
p!0.001). This represents a 7.5% reduction in activity per
volume fromusing sMRI-based plans. Notably, no difference
in activity-per-volume ratio was noted between TRUS-based
and erMRI-based plans ( p5 0.852) (Table 2).
Similar PTV coverage and improved dose homogeneity
with sMRI
To determine whether the decreased activity per volume
used with sMRI affected PTV coverage and homogeneity,
we compared dosimetric parameters between sMRI- andFig. 2. Overestimation of craniocaudal prostate length with transrectal ultrasound
patients, demonstrating implantation of seeds (red arrows) into the (a) urogenital diap
from using TRUS-based planning. (For interpretation of the references to color inTRUS-based plans. PTV coverage was similar between the
two modalities; the PTV V100 was slightly better for sMRI
(97.3% vs. 96.2%, p5 0.001), and the D90 was not signifi-
cantly different (116.6% for sMRI and 117.5% for TRUS,
p5 0.526). Dose homogeneity was improved with the
sMRI-based plans, as the mean V150 was 47.4% (vs. 53.8%
for TRUS, p5 0.001), and the mean V200 was 16.6% (vs.
19.2% for TRUS, p!0.001) (Table 2). Notably, R100 was
!1 cm3 and U200 was less than 0.07 cm
3 for all plans.
When comparing dosimetric parameters between erMRI-
and TRUS-based plans, it was noted that there was a small
difference in PTV coverage, with slightly better coverage for
the erMRI-based plans. Although the absolute differences
were small, they did reach statistical significance for both
the V100 ( p!0.001) and the D90 ( p5 0.025). Also, while
the V200 was lower for the erMRI-based plans ( p!0.001),
there was no difference in the V150 ( p5 0.156) (Table 2).
Discussion
To the authors’ knowledge, this is the first study to
directly compare TRUS, erMRI, and sMRI in terms of(TRUS). Postimplant T2-weighted axial magnetic resonance images from 2
hragmand (b) penile bulb as a consequence of overestimating prostate length
this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Treatment plans based on transrectal ultrasound (TRUS) vs. standard body array coil magnetic resonance imaging (sMRI) vs. endorectal MRI (erM-
RI). A representative midgland slice for 1 patient demonstrates needle and seed placement in plans calculated with (a) TRUS, (b) sMRI, or (c) erMRI. On the
erMRI-based plan, penetration of several needles through the anterior rectal wall would have been required to obtain adequate peripheral zone coverage along
the entire gland length. (Dark blue line indicates prostate; light blue line, planning target volume [PTV]; red line, 100% isodose curve; dark green line,
rectum; and green dots, seeds.) (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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We demonstrate that using sMRI instead of TRUS for bra-
chytherapy planning results in improved visualization of
prostate anatomy, and that using sMRI results in less
activity per volume required to achieve adequate PTV
coverage. It is also notable that sMRI-based plans had
improved dose homogeneity, as demonstrated by lower
mean V150 and V200 values with the use of sMRI. Moreover,Table 2
Radioactivity per prostate volume and dosimetric parameters
Parameter
TRUS sMRI erMRI
Measure Measure p-Value* Measure p-Value*
Activity per
volume (mCi/cm3)
0.974 0.901 !0.001 0.979 0.852
V100 (%) 96.2 97.3 0.001 98.4 !0.001
D90 (%) 117.5 116.6 0.526 120.4 0.025
V150 (%) 53.8 47.4 0.001 51.9 0.156
V200 (%) 19.2 16.6 !0.001 15.4 !0.001
TRUS5 transrectal ultrasound; sMRI5 standard body array coil
magnetic resonance imaging; erMRI5 endorectal coil magnetic resonance
imaging; mCi5millicurie; PTV V1005 percentage of PTV receiving
100% of the prescription dose; D90 = dose to 90% of the prostate; PTV
V1505 percentage of PTV receiving 150% of the prescription dose; PTV
V2005 percentage of PTV receiving 200% of the prescription dose;
MRI5magnetic resonance imaging.
*p-Values are for each MRI modality compared with TRUS.we found that the use of an endorectal coil induced consid-
erable distortion of the prostate, which suggests that erMRI
may not be the ideal imaging modality for brachytherapy
treatment planning.
Our results highlight the susceptibility of brachytherapy
treatment planning to changes in target delineation. Given
the rapid dose falloff inherent in brachytherapy, even minor
changes in target delineation can have a significant impact
on the accuracy of dose delivery. The sharper anatomic
detail visualized by MRI in treatment planning and delivery
would allow more accurate seed placement and perhaps
better control of the dose to be delivered. Ultimately, this
could result in decreased toxicity by reducing the radiation
dose to the bladder neck, rectum, urogenital diaphragm,
and penile bulb. For example, in one study of factors related
to penile bulb dose, postimplant MRI/CT fusion showed
that a decrease in the distance from the prostate apex to
the penile bulb (which ranged from 5 to 33 mm in that
study) correlated with increased penile bulb dose, with
approximately one-third of patients receiving potentially
clinically significant penile bulb doses (23). Increased dose
to the penile bulb has been associated with the development
of postbrachytherapy erectile dysfunction in several reports
(24, 25), although this association is not conclusive (26,
27). Regardless, the use of MRI for treatment planning
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ability to quantify dosimetric factors associated with
treatment-related morbidity.
Another possible benefit of better anatomic visualization
is improved control over dose heterogeneity. Accurate visu-
alization of prostate glandular tissue and the urethra would
allow improved urethral sparing and facilitate dose escala-
tion to dominant lesions. In fact, advanced MRI techniques
such as MRI spectroscopy have been explored for dose
escalation using brachytherapy (28, 29) and external beam
radiation therapy (30).
Successful implementation of MRI for pretreatment
planning will require the ability to use MRI guidance in
the operating room. The feasibility of intraoperative MRI
for prostate brachytherapy has been demonstrated by the
Brigham and Women’s/Dana Farber Cancer Center group
(18). In that series, an open MRI was used to perform the
implants with real-time intraoperative imaging, using intra-
operative planning and optimization. Another study from
the same group showed that prostate deformation is seen
with pretreatment erMRI when compared with intraopera-
tive MRI (31). These findings are consistent with the gland
deformation seen in the present study and underscore the
importance of accurate integration of pretreatment and in-
traoperative MRI, which is of particular importance when
using preplanning techniques.
Another means of using MRI in preplanning is MRI/
TRUS fusion. Fusing MRI to TRUS has been shown to be
feasible and to improve visualization of the prostate, particu-
larly with respect to identifying the base and apex slices on
TRUS (32, 33). Those studies demonstrated that TRUS
underestimated the extent of the prostate at both the base
and the apex. Conversely, we found that TRUSoverestimated
prostate length, highlighting the interoperator variability
inherent with TRUS; presumably this variability could be
improved by usingMRI/TRUS fusion. A previous dosimetric
study compared TRUS-based and MRI-based preplanning
and used MRI/TRUS fusion to confirm the reliability of
MRI for preplanning (34). Those investigators found almost
identical dosimetric parameters between the MRI- and
TRUS-based approaches, which would be expected because
they used identical seed and needle locations on both MRI
and TRUS followed by MRI/TRUS fusion, and did not inde-
pendently optimize the plans based on the anatomic detail
from each image as was done in the present study.
Our finding of prostate gland distortion with erMRI is
consistent with previous studies. Heijmink et al. (35) found
that introduction of an endorectal coil reduced mean pros-
tate volume by 17.9% compared with standard body array
coil MRI, which is comparable to the 13% reduction seen
in the present study. Those authors also found that the
endorectal coil led to significantly shorter mean anterior-
posterior diameter (5.38 mm), longer medial-lateral diam-
eter (3.49 mm), and longer craniocaudal length (2.24 mm)
( p!0.05 for all comparisons); all of these findings are
consistent with our results and with those from anotherstudy evaluating prostate distortion with erMRI (36).
However, to the authors’ knowledge, our study is the first
to directly evaluate erMRI for prostate brachytherapy pre-
planning and compare it with other imaging modalities.
From our analysis, we conclude that erMRI is not ideal
for treatment planning, because the resulting anatomic
distortion required nonstandard, often asymmetric loading
patterns, and also often required needles to track through
the rectum to achieve adequate peripheral zone coverage.
Given the susceptibility of brachytherapy treatment plan-
ning to minor changes in target delineation, the distortion
in prostate volume and dimensions with the endorectal coil
could result in major changes in the accuracy of dose
delivery; because the prostate will return to its normal
shape after the procedure, the erMRI-based plan does not
accurately represent the anatomy that exists for the duration
of treatment delivery. Notably, we used erMRI images for
the present study that were obtained for the purpose of
ruling out extraprostatic extension or seminal vesicle
involvement, and were thus optimized for this purpose.
erMRI may be more useful for treatment planning if it
was optimized for treatment planning, such as minimizing
anatomic distortion by filling the balloon less, and this
represents an interesting direction for future study.
There are several important limitations to the present
study that must be considered. For example, the retrospec-
tive nature of this study necessitated the use of scans
acquired at different time pointsdpreimplant TRUS and
erMRI images were used along with sMRI images acquired
30 days postimplant. This introduces the possibility that
postimplant edema could alter prostate volume and dimen-
sions and thus affect treatment planning on the postimplant
MRI. However, Crook et al. (37) demonstrated in a study of
241 patients that approximately 90% of postimplant edema
resolves at 1 month, although some patients may experi-
ence prolonged edema. Further, we found no significant
difference between the mean prostate volume using sMRI
compared with TRUS (33.9 cm3 sMRI vs. 32.5 cm3 TRUS,
p5 0.076). Therefore, we believe that using a 30-day post-
implant sMRI allows sufficient time for resolution of
edema to reasonably approximate preimplant volumes
and permit meaningful analysis of treatment planning
parameters. Furthermore, the lack of a mean volume differ-
ence between TRUS and sMRI suggests that the small
differences noted in medial-lateral and anterior-posterior
diameter between these two modalities are likely attribut-
able to the minor anatomic distortion caused by the TRUS
probe. Regardless, given the previously discussed suscepti-
bility of brachytherapy treatment planning to changes in
target delineation, the use of scans from different time
points does limit the interpretation of our data. Of note,
the visualization of the stranded seeds on the Day 30 sMRI
(Fig. 3b) did not affect treatment planning, as the images
were used only for anatomic delineation and the treatment
planning phase of the study considered only the defined
contours.
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one TRUS system with one operator. Given the well-
described interoperator variability when using TRUS (5e8),
it is possible that the volumetric and dosimetric comparisons
made inour studymaynot generalize to other centers. Further,
ultrasonographic technologies and techniques continue to
improve (38), and improved resolution and anatomic visuali-
zation with ultrasound may provide some of the same advan-
tages as MRI. Nevertheless, given some of the inherent
limitations of ultrasound, this initial volumetric and dosi-
metric analysis highlights some of the potential advantages
of using MRI for brachytherapy treatment planning.Conclusions
Improved imaging modalities will continue to help
enhance the quality and consistency of prostate brachyther-
apy, a particularly important consideration in an era when
improved quality control has become a major focus in radi-
ation oncology. In the present study, we provide data to
suggest that the improved anatomic detail visualized with
MRI may confer treatment planning advantages when
compared with TRUS. We further demonstrate the impor-
tance of considering the effect of imaging technique on
anatomy, as the prostate gland deformation seen with
staging erMRI resulted in planning challenges and could
lead to treatment inaccuracy. Future studies should continue
to evaluate the use of MRI in prostate brachytherapy treat-
ment planning and delivery.References
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